Pharmacotherapy for fibromyalgia

Frontiers in Pharmacology

Volumn MAR, Issue , 2011, Pages

  Smith, Howard S ^a   Bracken, Donna ^a   Smith, Joshua M ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b Pharmaceutical Research Institute   (United States)

Author keywords

Duloxetine; Efficacy; Fibromyalgia; Milnacipran; Pain; Pharmacotherapy; Pregabalin

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CYCLOBENZAPRINE; CYPROHEPTADINE; DESIPRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; GABAPENTIN; IMIPRAMINE; MILNACIPRAN; OXYBATE SODIUM; PARACETAMOL PLUS TRAMADOL; PAROXETINE; PLACEBO; PRAMIPEXOLE; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUBSTANCE P; TAPENTADOL; TIZANIDINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; BEDTIME DOSAGE; BLOOD PRESSURE; COGNITIVE THERAPY; CONSTIPATION; DIARRHEA; DIZZINESS; DOPAMINERGIC TRANSMISSION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EVENING DOSAGE; EXERCISE; FATIGUE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; HEART FAILURE; HEART RATE; HUMAN; HYPERALGESIA; INSOMNIA; LIVER FAILURE; MAJOR DEPRESSION; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; NOCICEPTION; PAIN THRESHOLD; PARKINSON DISEASE; PATHOGENESIS; PATIENT EDUCATION; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; QUESTIONNAIRE; RESTLESS LEGS SYNDROME; REVISED FIBROMYALGIA IMPACT QUESTIONNAIRE; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; TRIGGER POINT; VITAL SIGN; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; WIDESPREAD PAIN INDEX; XEROSTOMIA;

EID: 84861207376     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2011.00017     Document Type: Article

References (121)

1. Affaitati, G., Costantini, R., Fabrizio, A., Lapenna, D., Tafuri, E., and Giamberardino, M. A. (2011). Effects of treatment of peripheral pain gen-erators in fibromyalgia patients. Eur. J. Pain 15, 61-69.
2. Arnold, L. M., Clauw, D. J., Wohlreich, M. M., Wang, F., Ahl, J., Gaynor, P. J., and Chappell, A. S. (2009). Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials. Prim. Care Companion J. Clin. Psychiatry 11, 237-244.
3. Arnold, L. M., Gendreau, R. M., Palmer, R. H., Gendreau, J. F., and Wang, Y. (2010). Efficacy and safety of mil-nacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62, 2745-2756.
4. Arnold, L. M., Goldenberg, D. L., Stanford, S. B., Lalonde, J. K., Sandhu, H. S., Keck, P. E. Jr., Welge, J. A., Bishop, F., Stanford, K. E., Hess, E. V., and Hudson, J. I. (2007). Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 56, 1336-1344.
5. Arnold, L. M., Lu, Y., Crofford, L. J., Wohlreich, M., Detke, M. J., Ivengat, S., and Goldstein, D. J. (2004). A dou-ble-blind, multicenter trial comparing duloxetine with placebo in the treat-ment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 50, 2974-2984.
6. Arnold, L. M., Rosen, A., Prichett, Y. L., D'Souza, D. N., Goldstein, D. J., Iyengar, S., and Wernicke, J. F. (2005). A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119, 5-15.
7. Arnold, L. M., Russell, I. J., Diri, E. W., Duan, W. R., Young, J. P. Jr., Sharma, U., Martin, S. A., Barrett, J. A., and Haig, G. (2008). A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J. Pain 9, 792-805.
8. Barkin, R. L. (2008). Pregabalin: a critical review. Pain Med. Netw. 24, 8-9.
9. Bennett, R. (2005). The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin. Exp. Rheumatol. 23, S154-S162.
10. Bennett, R. M. (2001). Pharmacological treatment of fibromyalgia. J. Funct. Syndr. 1, 79-92.
11. Bennett, R. M., Friend, R., Jones, K. D., Ward, R., Han, B. K., and Ross, R. L. (2009a). The Revised Fibromyalgia Impact Questionnaire (FIQR): vali-dation and psychometric properties. Arthritis Res. Ther.11, R120.
12. Bennett, R. M., Bushmakin, A. G., Cappelleri, J. C., Zlateva, G., and Sadosky, A. B. (2009b). Minimal clinically important difference in the fibromyalgia impact questionnaire. J. Rheumatol. 36, 1304-1311.
13. Bennett, R. M., Jones, J., Turk, D. C., Russell, I. J., and Matallana, L. (2007). An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet. Disord. 8, 27. doi: 10.1186/1471-2474-8-27
14. Bennett, R. M., Kamin, M., Mrim, R., and Rosenthal, N. (2003). Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am. J. Med. 114, 537-545.
15. Bernard, A. L., Prince, A., and Edsall, P. (2000). Quality of life issues for fibro-myalgia patients. Arthritis Care Res. 13, 42-50.
16. Bernardy, K., Füber, N., Köllner, V., and Häuse, W. (2010). Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome -a system-atic review and metaanalysis of rand-omized controlled trials. J. Rheumatol. 37, 1991-2005.
17. Blanco, I., Béritze, N., Argüelles, M., Cárcaba, V., Fernández, F., Janciauskiene, S., Oikonomopoulou, K., de Serres, F. J., Fernández-Bustillo, E., and Hollenberg, M. D. (2010). Abnormal overexpression of mas-tocytes in skin biopsies of fibromy-algia patients. Clin. Rheumatol. 29, 1403-1412.
18. Bradley, L. A., and Alarcón, G. S. (1999). Is Chiari malformation associated with increased levels of substance P and clinical symptoms in persons with fibromyalgia? Arthritis Rheum. 42, 2731-2732.
19. Bradley, L. A., Alberts, K. R., Alarcón, G. S., Alexander, M. T., Mount, J. M., Weigent, D. A., Liu, H. G., Blalock, J. E., Aaron, L. A., Alexander, R. W., San Pedro, E. C., Martin, M. Y., and Morell, A. C. (1996). Abnormal brain regional cerebral blood flow and cerebrospinal fluid levels of substance P in patients and non-patients with fibromyalgia. Arthritis Rheum. 39, 1109.
20. Branco, J. C., Zahrisson, O., Perrot, S., Mainguy, Y. Multinational Coordinator Study Group. (2010). A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of mil-nacipran in treatment of fibromyalgia. J. Rheumatol. 37, 851-859.
21. Burgmer, M., Pogatzki-Zahn, E., Gaubitz, M., Wessoleck, E., Heuft, G., and Pfleiderer, B. (2009). Altered brain activity during pain processing in fibromyalgia. Neuroimage 44, 502-508.
22. Busch, A. J., Schachter, C. L., Overend, T. J., Peloso, P. M., and Barber, K. A. (2008). Exercise for fibromyalgia: a systematic review. J. Rheumatol. 35, 1130-1144.
23. Carville, S. F., Arendt-Nielsen, S., Bliddal, H., Blotman, F., Branco, J. C., Buskila, D., Da Silva, J. A., Danneskiold-Samsøe, B., Dincer, F., Henriksson, C., Henriksson, K. G., Kosek, E., Longley, K., McCarthy, G. M., Perrot, S., Puszczewicz, M., Sarzi-Puttini, P., Silman, A., Späth, M., Choy, E. H.; EULAR. (2008). EULAR evidence-based recommendations for the management of fibromyalgia syn-drome. Ann. Rheum. Dis. 67, 536-541.
24. Chappell, A. S., Littlejohn, G., Kajdasz, D. K., Scheinberg, M., D'Souza, D. N., and Moldofsky, H. (2009a). A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clin. J. Pain 25, 365-375.
25. Chappell, A. S., Bradley, L. A., Wiltse, C., Detke, M. J., D'Souza, D. N., and Spaeth, M. (2009b). A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int. J. Gen. Med. 1, 91-102.
26. Chou, R., Huffman, L. H. American Pain Society; American College of Physicians. (2007). Nonpharmacologic therapies for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical prac-tice guideline. Ann. Intern. Med. 147, 492-504.
27. Choy, E. H., Mease, P. J., Kajdasz, D. K., Wohlreich, M. M., Crits-Christoph, P., Walker, D. J., and Chappell, A. S. (2009). Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials. Clin. Rheumatol. 28, 1035-1044.
28. Clauw, D. J., Mease, P., Palmer, R. H., Gendreau, R. M., and Wang, Y. (2008). Milnacipran for the treat-ment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin. Ther. 30, 1988-2004.
29. Clauw, D. J., Schmidt, M., Radulovic, D., Singer, A., Katz, P., and Bresette, J. (1997). The relationship between fibromyalgia and interstitial cystitis. J. Psychiatr. Res. 31, 125-131.
30. Coaccioli, S., Varrassi, G., Sabatini, C., Marinangeli, F., Giuliani, M., and Puxeddu, A. (2008). Fibromyalgia: nosography and therapeutic perspec-tives. Pain Pract. 8, 190-201.
31. Cordero, M. D., Moreno-Fernández, A. M., Carmona-López, M. I., Sánchez-Alcázar, J. A., Rodríguez, A. F., Navas, P., and de Miguel, M. (2010). Mitochondrial dysfunction in skin biopsies and blood mononuclear cells from two cases of fibromyalgia patients. Clin. Biochem. 43, 1174-1176.
32. Crofford, L. J., Mease, P. J., Simpson, S. L., Young, J. P. Jr., Martin, S. A., Haig, G. M., and Sharma, U. (2008). Fibromyalgia relapse evaluation and efficacy for durability of meaning-ful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 136, 419-431.
33. Crofford, L. J., Rowbotham, M. C., Mease, P. J., Russell, I. J., Dworkin, R. H., Corbin, A. E., Young, J. P. Jr., LaMoreaux, L. K., Martin, S. A., Sharma, U. Pregabalin 1008-105 Study Group. (2005). Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52, 1264-1273.
34. Curran, M. P. (2009). Duloxetine: in patients with fibromyalgia. Drugs 69, 1217-1227.
35. de Souza, J. B., Potvin, S., Goffaux, P., Charest, J., and Marchand, S. (2009). The deficit of pain inhibition in fibromyalgia is more pronounced in patients with comorbid depressive symptoms. Clin. J. Pain 25, 123-127.
36. Desmeules, J. A., Cedraschi, C., Rapiti, E., Baumgartner, E., Finckh, A., Cohen, P., Dayer, P., and Vischer, T. L. (2003). Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum. 48, 1420-1429.
37. Di Piero, V., Jones, A. K., Iannotti, F., Powell, M., Perani, D., Lenzi, G. L., and Frackowiak, R. S. (1991). Chronic pain: a PET study of the central effects of percutaneous high cervical cordot-omy. Pain 46, 9-12.
38. Diers, M., Schley, M. T., Rance, M., Yilmaz, P., Lauer, L., Rukwied, R., Schmelz, M., and Flor, H. (2011). Differential central pain processing following repetitive intramuscular proton/prostaglandin E(2) injections in female fibromyalgia patients and healthy controls. Eur. J. Pain (in press).
39. Figueroa, A., Kingsley, J. D., McMillan, V., and Panton, L. B. (2008). Resistance exercise training improves heart rate variability in women with fibromyal-gia. Clin. Physiol. Funct. Imaging 28, 49-54.
40. Fishbain, D. A., Cutler, R., Rosomoff, H. L., and Rosomoff, R. S. (2000). Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review. Pain Med. 1, 310-316.
41. Geisser, M. E., Gracely, R. H., Giesecke, T., Petzke, F. W., Williams, D. A., and Clauw, D. J. (2007). The association between experimental and clinical pain measures among persons with fibromyalgia and chronic fatigue syndrome. Eur. J. Pain 11, 202-207.
42. Geisser, M. E., Palmer, R. H., Gendreau, R. M., Wang, Y., and Clauw, D. J. (2011). A pooled analysis of two randomized, double-blind, placebo-controlled tri-als of milnacipran monotherapy in the treatment of fibromyalgia. Pain Pract. 11, 120-131.
43. Gendreau, R. M., Thorn, M. D., Gendreau, J. F., Kranzler, J. D., Ribeiro, S., Gracely, R. H., Williams, D. A., Mease, P. J., McLean, S. A., and Clauw, D. J. (2005). Efficacy of milnacipran in patients with fibromyalgia. J. Rheumatol. 32, 1975-1985.
44. Gerster, J. C., and Hadj-Djilani, A. (1984). Hearing and vestibular abnormalities in primary fibrositis syndrome. J. Rheumatol. 11, 678-680.
45. Giesecke, J., Reed, B. D., Haefner, H. K., Giesecke, T., Clauw, D. J., and Gracely, R. H. (2004). Quantitative sensory testing in vulvodynia patients and increased peripheral pressure pain sensitivity. Obstet. Gynecol. 104, 126-133.
46. Giesecke, T., Gracely, R. H., Williams, D. A., Geisser, M. E., Petzke, F. W., and Clauw, D. J. (2005). The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum. 52, 1577-1584.
47. Goldenberg, D. L. (1989). Treatment of fibromyalgia syndrome. Rheum. Dis. Clin. North Am. 15, 61-71.
48. Goldenberg, D. L., Clauw, D. J., Palmer, R. H., Mease, P., Chen, W., and Gendreau, R. M. (2010). Durability of therapeu-tic response to milnacipran treatment for fibromyalgia. Results of a rand-omized, double-blind, monotherapy 6-month extension study. Pain Med. 11, 180-194.
49. Gracely, R. H., Petzke, F., Wolf, J. M., and Clauw, D. J. (2002). Functional magnetic resonance imaging evi-dence of augmented pain processing in fibromyalgia. Arthritis Rheum. 46, 1333-1343.
50. Gürsoy, S., Erdal, E., Herken, H., Madenci, E., Alaşehirli, B., and Erdal, N. (2003). Significance of catechol-O-methyl-transferase gene polymorphism in fibromyalgia syndrome. Rheumatol. Int. 23, 104-107.
51. Hassett, A. L., and Gevirtz, R. N. (2009). Nonpharmacologic treatment for fibromyalgia: patient education, cog-nitive-behavioral therapy, relaxation techniques, and complementary and alternative medicine. Rheum. Dis. Clin. North Am. 35, 393-407.
52. Häuser, W., Petzke, F., and Sommer, C. (2010). Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J. Pain 11, 505-521.
53. Holman, A. J., and Myers, R. R. (2005). A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. 52, 2495-2505.
54. Hsieh, J. C., Stahle-Backdahl, M., Hagermark, O., Stone-Elander, S., Rosenquist, G., and Ingvar, M. (1996). Traumatic nociceptive pain activates the hypothalamus and the periaq-ueductal gray: a positron emission tomography study. Pain 64, 303-314.
55. Jones, J., Rutledge, D. N., Jones, K. D., Matallana, L., and Rooks, D. S. (2008). Self-assessed physical function lev-els of women with fibromyalgia: a national survey. Womens Health Issues 18, 406-412.
56. Jones, K. D., Burckhardt, C. S., Clark, S. R., Bennett, R. M., and Potempa, K. M. (2002). A randomized controlled trial of muscle strengthening versus flexibility training in fibromyalgia. J. Rheumatol. 29, 1041-1048.
57. Jones, K. D., and Liptan, G. L. (2009). Exercise interventions in fibromy-algia: clinical applications from the evidence. Rheum. Dis. Clin. North Am. 35, 373-391.
58. Kim, S. H., Kim, D. H., Oh, D. H., and Claud, D. J. (2008). Characteristic electron microscopic findings in the skin of patients with fibromyalgia -preliminary study. Clin. Rheumatol. 27, 407-411.
59. Langemark, M., Jensen, K., Jensen, T. S., and Olesen, J. (1989). Pressure pain thresholds and thermal nociceptive thresholds in chronic tension-type headache. Pain 38, 203-210.
60. Lui, Z., Welin, M., Bragee, B., and Nyberg, F. (2000). A high-recovery extraction procedure for quantitative analysis of substance P and opioid peptides in human cerebropinal fluid. Peptides 21, 853-860.
61. Maixner, W., Fillingim, R., Booker, D., and Sigurdsson, A. (1995). Sensitivity of patients with painful temporoman-dibular disorders to experimentally evoked pain. Pain 63, 341-351.
62. Mease, P. J., Clauw, D. J., Gendreau, R. M., Rao, S. G., Kranzler, J., Chen, W., and Palmer, R. H. (2009). The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J. Rheumatol. 36, 398-409.
63. Mease, P. J., Russell, I. J., Arnold, L. M., Florian, H., Young, J. P. Jr., Martin, S. A., and Sharma, U. (2008). A rand-omized, double-blind, placebo-con-trolled, phase III trial of pregabalin in the treatment of patients with fibro-myalgia. J. Rheumatol. 35, 502-514.
64. Miedema, H. S., van der Linden, S. M., Rasker, J. J., and Valkenburg, H. A. (1998). National database of patients visiting rheumatologists in The Netherlands: the standard diagno-sis register of rheumatic diseases. A report and preliminary analysis. Br. J. Rheumatol. 37, 555-561.
65. Ness, T. J., Powell-Boone, T., Cannon, R., Lloyd, L. K., and Fillingim, R. B. (2005). Psychophysical evidence of hypersensitivity in subjects with inter-stitial cystitis. J. Urol. 173, 1983-1987.
66. Nishishinya, B., Urrútia, G., Walitt, B., Rodriguez, A., Bonfill, X., Alegre, C., and Darko, G. (2008). Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. Rheumatology (Oxford) 47, 1741-1746.
67. Normand, E., Potvin, S., Gaumond, I., Cloutier, G., Corbin, J. F., and Marchand, S. (2011). Pain inhibition is deficient in chronic widespread pain but normal in major depressive dis-order. J. Clin. Psychiatry 72, 219-224.
68. Otto, M., Bach, F. W., Jensen, T. S., Brøsen, K., and Sindrup, S. H. (2008). Escitalopram in painful polyneuropa-thy: a randomized, placebo-control-led, cross-over trial. Pain 139, 275-283.
69. Pattany, P. M., Yezierski, R. P., Widerstrom-Noga, E. G., Bowen, B. C., Martinez-Arizala, A., Garcia, B. R., and Quencer, R. M. (2002). Proton magnetic reso-nance spectroscopy of the thalamus in patients with chronic neuropathic pain after spinal cord injury. AJNR Am. J. Neuroradiol. 23, 901-905.
70. Rodrigues, A. C., Nicholas, V. G., Schmidt, S., and Mauderli, A. P. (2005). Hypersensitivity to cutaneous thermal nociceptive stimuli in irritable bowel syndrome. Pain 115, 5-11.
71. Rooks, D. S., Gautam, S., Romeling, M., Cross, M. L., Stratigakis, D., Evans, B., Goldernberg, D. L., Iverson, M. D., and Katz, J. N. (2007). Group exercise, edu-cation, and combination self-manage-ment in women with fibromyalgia: a randomized trial. Arch. Intern. Med. 167, 2192-2200.
72. Russell, I. J., Kamin, M., Bennett, R. M., Schnitzer, T. J., Gren, J. A., and Katz, W. A. (2000). Efficacy of tramodol in treatment of pain in fibromylagia. J. Clin. Rheumatol. 6, 250-257.
73. Russell, I. J., Mease, P. J., Smith, T. R., Kajdasz, D. K., Wohlreich, M. M., Detke, M. J., Walker, D. J., Chappell, A. S., and Arnold, L. M. (2008). Efficacy and safety of duloxetine for treat-ment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136, 432-444.
74. Russell, I. J., Michalek, J. E., Xiao, Y., Haynes, W., Vertiz, R., and Lawrence, R. A. (2002). Therapy with a central alpha 2-adrenergic agonist (tizani-dine) decreases cerebrospinal fluid substance P, and may reduce serum hyaluronic acid as it improves the clinical symptoms of the fibromyalgia syndrome. Arthritis Rheum. 46, S614.
75. Russell, I. J., Orr, M. D., Littman, B., Vipraio, G. A., Alboukrek, D., Michalek, J. E., Lopez, Y., and MacKillip, F. (1994). Elevated cerebrospinal fluid levels of substance P in patients with the fibro-myalgia syndrome. Arthritis Rheum. 37, 1593-1601.
76. Russell, I. J., Perkins, A. T., Michalek, J. E., and Oxybate SXB-26 Fibromyalgia Syndrome Study Group. (2009). Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multi-center clinical trial. Arthritis Rheum. 60, 299-309.
77. Russell, I. J., Vaeroy, H., Javors, M., and Nyberg, F. (1992). Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 35, 550-556.
78. Sarchielli, P., Di Filippo, M., Nardi, K., and Calabresi, P. (2007a). Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr. Pain Headache Rep. 11, 343-351.
79. Sarchielli, P., Mancini, M. L., Floridi, A., Coppola, F., Rossi, C., Nardi, K., Acciarresi, M., Pini, L. A., and Calabresi, P. (2007b). Increased levels of neurotrophins are not specific for chronic migraine: evidence from pri-mary fibromyalgia syndrome. J. Pain 8, 737-745.
80. Sayar, K., Aksu, G., Ak, I., and Tosun, M. (2003). Venlafaxine treatment of fibromyalgia. Ann. Pharmacother. 37, 1561-1565.
81. Scharf, M. B., Baumann, M., and Berkowitz, D. V. (2003). The effects of sodium oxybate on clinical symp-toms and sleep patterns in patients with fibromyalgia. J. Rhematol. 30, 1070-1074.
82. Smith, H. S. (2009). The Pathophysiology of Fibromyalgia as part of National Lecture Series. Baltimore: John Hopkins Medical Institute.
83. Smith, H. S., and Barkin, R. L. (2010). Fibromyalgia syndrome: a discussion of the syndrome and pharmacother-apy. Am. J. Ther. 17, 418-439.
84. Smith, H. S., Harris, R. E., and Claue, D. J. (2011). Fibromyalgia: an affer-ent processing disorder leading to a complex pain generalized syndrome. Pain Physician (in press).
85. Stahl, S. M., Grady, M. M., Moret, C., and Briley, M. (2005). SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 10, 732-747.
86. Staud, R. (2010). Is it all central sensitiza-tion? Role of peripheral tissue nocice-ption in chronic musculoskeletal pain. Curr. Rheumatol. Rep. 12, 448-454.
87. Staud, R., Bovee, C. E., Robinson, M. E., and Price, D. D. (2008a). Cutaneous C-fiber pain abnormalities of fibro-myalgia patients are specifically related to temporal summation. Pain 139, 315-323.
88. Staud, R., Craggs, J. G., Perlstein, W. M., Robinson, M. E., and Price, D. D. (2008b). Brain activity associated with slow temporal summation of C-fiber evoked pain in fibromyalgia patients and healthy controls. Eur. J. Pain 12, 1078-1089.
89. Staud, R., Cannon, R. C., Mauderli, A. P., Robinson, M. E., Price, D. D., and Vierck, C. J. Jr. (2003a). Temporal summation of pain from mechanical stimulation of muscle tissue in normal controls and subjects with fibromyal-gia syndrome. Pain 102, 87-95.
90. Staud, R., Robinson, M. E., Vierck, C. J. Jr., Cannon, R. C., Mauderli, A. P., and Price, D. D. (2003b). Ratings of experimental pain and pain-related negative affect predict clinical pain in patients with fibromyalgia syndrome. Pain 105, 215-222.
91. Staud, R., Robinson, M. E., Vierck, C. J. Jr., and Price, D. D. (2003c). Diffuse noxious inhibitory controls (DNIC) attenuate temporal summation of second pain in normal males but not in normal females or fibromyalgia patients. Pain 101, 167-174.
92. Staud, R., Nagel, S., Robinson, M. E., and Price, D. D. (2009). Enhanced central pain processing of fibromyal-gia patients is maintained by muscle afferent input: a randomized, double-blind, placebo-controlled study. Pain 145, 96-104.
93. Staud, R., Price, D. D., Robinson, M. E., Mauderli, A. P., and Vierck, C. J. (2004). Maintenance of windup of second pain requires less frequent stimulation in fibromyalgia patients compared to normal controls. Pain 110, 689-696.
94. Staud, R., Robinson, M. E., and Price, D. D. (2007). Temporal summation of second pain and its maintenance are useful for characterizing widespread central sensitization of fibromyalgia patients. J. Pain 8, 893-901.
95. Staud, R., Vierck, C. J., Cannon, R. L., Mauderli, A. P., and Price, D. D. (2001). Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syn-drome. Pain 91, 165-175.
96. Straube, S., Derry, S., Moore, R. A., and McQuay, H. J. (2010). Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 49, 706-715.
97. Thieme, K., Flor, H., and Turk, D. (2006). Psychological pain treatment in fibro-myalgia syndrome: efficacy of operant behavioural and cognitive behavioural treatments. Arthritis Res. Ther. 8, 121-132.
98. Thieme, K., and Gracely, R. H. (2009). Are psychological treatments effective for fibromyalgia pain? Curr. Rheumatol. Rep. 11, 443-450.
99. Thomas, E. N., and Blotman, F. (2010). Aerobic exercise in fibromyalgia: a practical review. Rheumatol. Int. 30, 1143-1150.
100. Tofferi, J. K., Jackson, J. L., and O'Malley, P. G. (2004). Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum. 51, 9-13.
101. Uçeyler, N., Häuser, W., and Sommer, C. (2008). A systematic review on the effectiveness of treatment with anti-depressants in fibromyalgia syndrome. Arthritis Rheum. 59, 1279-1298.
102. Uçeyler, N., Valenza, R., Stock, M., Schedel, R., Sprotte, G., and Sommer, C. (2006). Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. Arthritis Rheum. 54, 2656-2664.
103. Vaerøy, H., Helle, R., Førre, O., Kåss, E., and Terenius, L. (1988). Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 32, 21-26.
104. Valkeinen, H., Alen, M., Hakkinen, A., Hannonen, P., Kukkonen-Harjula, K., and Häkkinen, K. (2008). Effects of concurrent strength and endurance training on physical fitness and symp-toms in postmenopausal women with fibromyalgia: a randomized control-led trial. Arch. Phys. Med. Rehabil. 89, 1660-1666.
105. Vitton, O., Gendreau, M., Gendreau, J., Kranzler, J., and Rao, S. G. (2004). A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum. Psychopharmacol. 19, S27-S35.
106. Wang, H., Moser, M., Schiltenwolf, M., and Buchner, M. (2008). Circulating cytokine levels compared to pain in patients with fibromyalgia -a pro-spective longitudinal study over 6 months. J. Rheumatol. 35, 1366-1370.
107. Wilke, W. S. (2009). New developments in the diagnosis of fibromyalgia syn-drome: say goodbye to tender points? Cleve. Clin. J. Med. 76, 345-352.
108. Williams, D. A. (2005). "Cognitive and behavioral approaches to chronic pain," in Fibromyalgia and Other Control Pain Syndromes, eds D. J. Wallace and D. J. Clauw (Philadelphia, PA: Lippincott Williams & Wilkins), 343-352.
109. Wolfe, F. (2003). Pain extent and diag-nosis: development and validation of the regional pain scale in 12,799 patients with rheumatic disease. J. Rheumatolol. 30, 369-378.
110. Wolfe, F. (2010). New American College of Rheumatology criteria for fibromy-algia: a twenty-year journey. Arthritis Care Res. (Hoboken) 62, 583-584.
111. Wolfe, F., Clauw, D. J., Fitzcharles, M. A., Goldenberg, D. L., Katz, R. S., Mease, P., Russell, A. S., Russell, I. J., Winfield, J. B., and Yunus, M. B. (2010). The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. (Hoboken) 62, 600-610.
112. Wolfe, F., Ross, K., Anderson, J., Russell, I. J., and Hebert, L. (1995). The preva-lence and characteristics of fibromyal-gia in the general population. Arthritis Rheum. 38, 19-28.
113. Wood, P. B., Patterson, J. C. II, Sunderland, J. J., Tainter, K. H., Glabus, M. F., and Lilien, D. L. (2007). Reduced presyn-aptic dopamine activity in fibromy-algia syndrome demonstrated with positron emission tomography: a pilot study. J. Pain 8, 51-58.
114. Woolf, C. J. (2011). Central sensitization: implications for the diagnosis and treatment of pain. Pain 152, s2-s15.
115. Xu, X. J., Dalsgaard, C. J., and Wiesenfeld-Hallin, Z. (1992). Spinal substance P and N-methyl-D-aspartate receptors are coactivated in the induction of central sensitization of the nociceptive flexor reflex. Neuroscience 51, 641-648.
116. Yarnitsky, D. (2010). Conditioned pain modulation (the diffuse noxious inhibitory control-like effect): its rele-vance for acute and chronic pain states. Curr. Opin. Anaesthesiol. 23, 611-615.
117. Yarnitsky, D., Arendt-Nielsen, L., Bouhassira, D., Edwards, R. R., Fillingim, R. B., Granot, M., Hansson, P., Lautenbacher, S., Marchand, S., and Wilder-Smith, O. (2010). Recommendations on terminology and practice of psychophysical DNIC testing. Eur. J. Pain 14, 339.
118. Younger, J., and Mackey, S. (2009). Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 10, 663-672.
119. Yunus, M. B. (1984). Primary fibromyalgia syndrome: current concepts. Compr. Ther. 10, 21-28.
120. Yunus, M. B. (2008). Central sensitiv-ity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin. Arthritis Rheum. 37, 339-352.
121. Zhao, P., Waxman, S. G., and Hains, B. C. (2007). Modulation of thalamic nocic-eptive processing after spinal cord injury through remote activation of thalamic microglia by cysteine cysteine chemok-ine ligand 21. J. Neurosci. 27, 8893-8902.